OncoSynergy Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.61M
- Investors
-
18
OncoSynergy General Information
Description
Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies employ a transformative strategy based on the principle of resistance mechanism inhibitors that inhibit several cancer-driving pathways simultaneously, enabling oncologists to provide durable outcomes and cures for patients.
Contact Information
Website
www.oncosynergy.comCorporate Office
- 850 Pacific Street
- Unit 1802
- Stamford, CT 06903
- United States
Corporate Office
- 850 Pacific Street
- Unit 1802
- Stamford, CT 06903
- United States
OncoSynergy Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 26-May-2026 | $6.61M | Completed | Clinical Trials - Phase 1 | ||
| 10. Later Stage VC | 13-May-2022 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC | 08-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 20-Sep-2019 | Completed | Clinical Trials - General | |||
| 7. Grant | 01-Jan-2019 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC (Series A) | 14-May-2018 | Completed | Clinical Trials - General | |||
| 5. Accelerator/Incubator | 19-May-2017 | Completed | Clinical Trials - General | |||
| 4. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 3. Merger/Acquisition | 05-Apr-2016 | Cancelled | Clinical Trials - General | |||
| 2. Equity Crowdfunding | 28-Jun-2015 | $178K | $178K | Completed | Clinical Trials - General |
OncoSynergy Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
OncoSynergy Comparisons
Industry
Financing
Details
OncoSynergy Competitors (42)
One of OncoSynergy’s 42 competitors is Oxford Biotherapeutics, a Private Equity-Backed company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oxford Biotherapeutics | Private Equity-Backed | Oxford, United Kingdom | ||||
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY | ||||
| Centrose | Venture Capital-Backed | Madison, WI |
OncoSynergy Patents
OncoSynergy Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013370467-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Active | 26-Dec-2012 | ||
| AU-2013370467-B2 | Anti- integrin beta1 antibody compositions and methods of use thereof | Active | 26-Dec-2012 | ||
| AU-2018260887-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Inactive | 26-Dec-2012 | ||
| EP-2938359-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Inactive | 26-Dec-2012 | ||
| EP-2938359-A4 | Anti- integrin beta1 antibody compositions and methods of use thereof | Inactive | 26-Dec-2012 | C07K16/2842 |
OncoSynergy Signals
OncoSynergy Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| UCSF Innovation Ventures | Venture Capital | Minority | ||
| National Cancer Institute | Government | |||
| National Institutes of Neurological Disorders and Stroke | Government | |||
| Connecticut Innovations | Venture Capital | Minority | ||
| Korea Information & Communications | Corporation | Minority |
OncoSynergy Acquisitions (1)
OncoSynergy’s most recent deal was a Merger/Acquisition with NexGenix Pharmaceuticals. The deal was made on 01-May-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NexGenix Pharmaceuticals | 01-May-2013 | Merger/Acquisition | Drug Discovery |
OncoSynergy FAQs
-
When was OncoSynergy founded?
OncoSynergy was founded in 2011.
-
Where is OncoSynergy headquartered?
OncoSynergy is headquartered in Stamford, CT.
-
What is the size of OncoSynergy?
OncoSynergy has 4 total employees.
-
What industry is OncoSynergy in?
OncoSynergy’s primary industry is Drug Discovery.
-
Is OncoSynergy a private or public company?
OncoSynergy is a Private company.
-
What is OncoSynergy’s current revenue?
The current revenue for OncoSynergy is .
-
How much funding has OncoSynergy raised over time?
OncoSynergy has raised $36.2M.
-
Who are OncoSynergy’s investors?
UCSF Innovation Ventures, National Cancer Institute, National Institutes of Neurological Disorders and Stroke, Connecticut Innovations, and Korea Information & Communications are 5 of 18 investors who have invested in OncoSynergy.
-
Who are OncoSynergy’s competitors?
Oxford Biotherapeutics, Meditope Biosciences, Mabworks Biotech, Innovimmune Biotherapeutics, and Centrose are some of the 42 competitors of OncoSynergy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process